title: Safety and efficacy of injectable and oral maropitant, a selective neurokinin 1 receptor antagonist, in a randomized clinical trial for treatment of vomiting in dogs.
abstract: Maropitant (Cerenia), a selective neurokinin(1) receptor antagonist, was evaluated for safety and efficacy in treatment and prevention of acute vomiting due to various etiologies in dogs in a randomized clinical trial. Two-hundred seventy-eight dogs were enrolled from 29 veterinary hospitals. Two-hundred fifty-two were evaluable for efficacy, while 275 were evaluable for safety. A randomized block design was utilized (three maropitant- and one placebo-treated dog per block). Initial treatment was maropitant at 1 mg/kg body weight (0.45 mg/lb) or an equivalent volume of saline (placebo) administered subcutaneously. On the subsequent 1 to 4 days, maropitant or placebo (dependent on allocation) was administered subcutaneously or orally at approximate 24-h intervals as needed. Oral doses were administered as maropitant tablets using unit dosing to deliver a minimum dose of 2 mg/kg body weight (0.9 mg/lb) or equivalent numbers of similar placebo tablets. Dogs and housing were observed twice daily for evidence of vomiting. Emesis was significantly (P <or= 0.0012) reduced in maropitant-treated dogs as 50% (32/64) of placebo-treated dogs continued to vomit compared to only 21.8% (41/188) of maropitant-treated dogs. Post-treatment clinical signs were consistent with clinical diagnoses and judged not to be treatment related. In this clinical trial, maropitant was safe and effective in reducing emesis due to various etiologies in dogs.
authors.affiliation: Veterinary Medicine Research & Development, Pfizer Inc, Kalamazoo, MI 49001, USA.
authors.forename: D S
authors.initials: DS
authors.lastname: Ramsey
authors.forename: K
authors.initials: K
authors.lastname: Kincaid
authors.forename: J A
authors.initials: JA
authors.lastname: Watkins
authors.forename: J F
authors.initials: JF
authors.lastname: Boucher
authors.forename: G A
authors.initials: GA
authors.lastname: Conder
authors.forename: J S
authors.initials: JS
authors.lastname: Eagleson
authors.forename: R G
authors.initials: RG
authors.lastname: Clemence
mesh_terms: D000284:Administration, Oral; D000818:Animals; D004285:Dogs; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D007279:Injections, Subcutaneous; D008297:Male; D064729:Neurokinin-1 Receptor Antagonists; D011812:Quinuclidines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D014839:Vomiting / Q000188:drug therapy / Q000209:etiology / Q000662:veterinary*
chemical_list: D064729:Neurokinin-1 Receptor Antagonists; D011812:Quinuclidines; C518176:maropitant